Home

Xenetic Biosciences, Inc. - Common Stock (XBIO)

9.2400
-1.1200 (-10.81%)
NASDAQ · Last Trade: Oct 9th, 1:42 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
4 Stocks In The Same Sector Just Made A Huge Leap In Momentum Rankingsbenzinga.com
Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names have been picking up steam as the market rally broadens and major indexes continue to reach new highs. Here's a look at four stocks flashing strong momentum signals.
Via Benzinga · October 9, 2025
Which stocks are moving before the opening bell on Thursday?chartmill.com
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · October 9, 2025
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · October 9, 2025
Xenetic Biosciences: Q3 Earnings Insightsbenzinga.com
Via Benzinga · November 10, 2023
Lack Of Catalysts Prompts Analyst To Downgrade Xenetic Biosciencesbenzinga.com
Via Benzinga · May 16, 2023
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · October 8, 2025
Nasdaq Gains 150 Points; US Mortgage Applications Declinebenzinga.com
Via Benzinga · October 8, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 8, 2025
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · October 8, 2025
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Via Benzinga · June 30, 2025
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Via Benzinga · June 23, 2025
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · September 30, 2024
XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024investorplace.com
XBIO stock results show that Xenetic Biosciences met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 13, 2024
XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q1 2024investorplace.com
XBIO stock results show that Xenetic Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024
XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q4 2023investorplace.com
XBIO stock results show that Xenetic Biosciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 22, 2024
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · December 5, 2023
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Gainers
Via Benzinga · June 20, 2023
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga.com
Via Benzinga · May 12, 2023
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Sessionbenzinga.com
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.
Via Benzinga · May 15, 2023
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Interventionbenzinga.com
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of the abortion pill mifepristone. 
Via Benzinga · April 13, 2023
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rulesbenzinga.com
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.
Via Benzinga · April 13, 2023
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medicationsbenzinga.com
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this week.
Via Benzinga · April 12, 2023
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Aheadbenzinga.com
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating risks to millions of people," including those in states where abortion remains legal.
Via Benzinga · April 11, 2023
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · April 11, 2023
US Judge Weighs Nationwide Ban On Abortion Pillsbenzinga.com
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is reportedly considering a request by anti-abortion groups to ban sales of the drug nationwide.
Via Benzinga · March 16, 2023